While AAT augmentation therapies (intravenous or aerosolized form) proved to be safe and well tolerated in emphysema patients with inherited AAT deficiency, the therapeutic benefit in CF lung disease remains to be determined. This evidence concerns the gene SERPINA1 and cystic fibrosis.